中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2013年
28期
2220-2224
,共5页
蔡莎莎%朱尤庆%朱晓文%张虎%梅娟娟
蔡莎莎%硃尤慶%硃曉文%張虎%梅娟娟
채사사%주우경%주효문%장호%매연연
碘乙酰胺%结肠炎,溃疡性%白细胞介素8%肿瘤坏死因子α%白云母
碘乙酰胺%結腸炎,潰瘍性%白細胞介素8%腫瘤壞死因子α%白雲母
전을선알%결장염,궤양성%백세포개소8%종류배사인자α%백운모
Iodoacetamide%Colitis,ulcerative%Interleukin-8%Tumor necrosis factor-alpha%Peroxidase%Muscovite
目的 探讨白云母对碘乙酰胺诱导的大鼠溃疡性结肠炎的作用及其可能机制.方法 雌性SD大鼠通过直肠给药注入碘乙酰胺,诱导溃疡性结肠炎模型.48只大鼠用随机数字表法分成6组:对照组、模型组、低剂量白云母组(360 mg/kg)、高剂量白云母组(720 mg/'kg)、5-氨基水杨酸(5-ASA)组和白云母联合5-ASA组(联合治疗组),每组8只.药物治疗7d后评估各组大鼠体重、疾病活动指数(DAI)、形态学损伤和组织学评分.用酶联免疫吸附试验检测肿瘤坏死因子α(TNF-α)、白细胞介素8(IL-8)的浓度和髓过氧化物酶(MPO)的活力,免疫组织化学方法评价核因子κB的活性.组间比较采用方差分析或秩和检验.结果 各组大鼠的治疗后体重、形态学评分、组织学评分、血浆TNF-α浓度,肠组织MPO活力和核因子κB活性均与白云母剂量显著相关(r=0.573、-0.647、-0.569、-0.681、-0.811、-0.842,均P＜0.05).高剂量白云母组与5-ASA组相比在治疗后体重、DAI、形态学损伤、组织学评分、IL-8浓度、TNF-α浓度、MPO活力、核因子κB活力方面差异均无统计学意义[(166±5)比(167±5)g,0.33(0.00,1.17)比0.17(0.00,0.83),2.50(2.00,4.00)比3.00(2.00,3.00),3.00(2.00,3.00)比2.50(2.00,3.00),(109±17)比(111±15) pg/ml,(166±38)比(155±45) pg/ml,(52±6)比(49±4) U/g,7.39±0.42比7.41±0.34,均P＞0.05].联合治疗组的MPO活力和核因子κB活性低于5-ASA组[(40±4)比(49±4)U/g、4.67±0.72比7.41±0.34,均P＜0.05],其余指标与5-ASA组差异均无统计学意义(均P＞0.05).结论 白云母直肠给药可以改善碘乙酰胺诱导的大鼠实验性结肠炎症,其机制可能与调节炎症反应有关.白云母有望成为溃疡性结肠炎治疗的候选药物.
目的 探討白雲母對碘乙酰胺誘導的大鼠潰瘍性結腸炎的作用及其可能機製.方法 雌性SD大鼠通過直腸給藥註入碘乙酰胺,誘導潰瘍性結腸炎模型.48隻大鼠用隨機數字錶法分成6組:對照組、模型組、低劑量白雲母組(360 mg/kg)、高劑量白雲母組(720 mg/'kg)、5-氨基水楊痠(5-ASA)組和白雲母聯閤5-ASA組(聯閤治療組),每組8隻.藥物治療7d後評估各組大鼠體重、疾病活動指數(DAI)、形態學損傷和組織學評分.用酶聯免疫吸附試驗檢測腫瘤壞死因子α(TNF-α)、白細胞介素8(IL-8)的濃度和髓過氧化物酶(MPO)的活力,免疫組織化學方法評價覈因子κB的活性.組間比較採用方差分析或秩和檢驗.結果 各組大鼠的治療後體重、形態學評分、組織學評分、血漿TNF-α濃度,腸組織MPO活力和覈因子κB活性均與白雲母劑量顯著相關(r=0.573、-0.647、-0.569、-0.681、-0.811、-0.842,均P＜0.05).高劑量白雲母組與5-ASA組相比在治療後體重、DAI、形態學損傷、組織學評分、IL-8濃度、TNF-α濃度、MPO活力、覈因子κB活力方麵差異均無統計學意義[(166±5)比(167±5)g,0.33(0.00,1.17)比0.17(0.00,0.83),2.50(2.00,4.00)比3.00(2.00,3.00),3.00(2.00,3.00)比2.50(2.00,3.00),(109±17)比(111±15) pg/ml,(166±38)比(155±45) pg/ml,(52±6)比(49±4) U/g,7.39±0.42比7.41±0.34,均P＞0.05].聯閤治療組的MPO活力和覈因子κB活性低于5-ASA組[(40±4)比(49±4)U/g、4.67±0.72比7.41±0.34,均P＜0.05],其餘指標與5-ASA組差異均無統計學意義(均P＞0.05).結論 白雲母直腸給藥可以改善碘乙酰胺誘導的大鼠實驗性結腸炎癥,其機製可能與調節炎癥反應有關.白雲母有望成為潰瘍性結腸炎治療的候選藥物.
목적 탐토백운모대전을선알유도적대서궤양성결장염적작용급기가능궤제.방법 자성SD대서통과직장급약주입전을선알,유도궤양성결장염모형.48지대서용수궤수자표법분성6조:대조조、모형조、저제량백운모조(360 mg/kg)、고제량백운모조(720 mg/'kg)、5-안기수양산(5-ASA)조화백운모연합5-ASA조(연합치료조),매조8지.약물치료7d후평고각조대서체중、질병활동지수(DAI)、형태학손상화조직학평분.용매련면역흡부시험검측종류배사인자α(TNF-α)、백세포개소8(IL-8)적농도화수과양화물매(MPO)적활력,면역조직화학방법평개핵인자κB적활성.조간비교채용방차분석혹질화검험.결과 각조대서적치료후체중、형태학평분、조직학평분、혈장TNF-α농도,장조직MPO활력화핵인자κB활성균여백운모제량현저상관(r=0.573、-0.647、-0.569、-0.681、-0.811、-0.842,균P＜0.05).고제량백운모조여5-ASA조상비재치료후체중、DAI、형태학손상、조직학평분、IL-8농도、TNF-α농도、MPO활력、핵인자κB활력방면차이균무통계학의의[(166±5)비(167±5)g,0.33(0.00,1.17)비0.17(0.00,0.83),2.50(2.00,4.00)비3.00(2.00,3.00),3.00(2.00,3.00)비2.50(2.00,3.00),(109±17)비(111±15) pg/ml,(166±38)비(155±45) pg/ml,(52±6)비(49±4) U/g,7.39±0.42비7.41±0.34,균P＞0.05].연합치료조적MPO활력화핵인자κB활성저우5-ASA조[(40±4)비(49±4)U/g、4.67±0.72비7.41±0.34,균P＜0.05],기여지표여5-ASA조차이균무통계학의의(균P＞0.05).결론 백운모직장급약가이개선전을선알유도적대서실험성결장염증,기궤제가능여조절염증반응유관.백운모유망성위궤양성결장염치료적후선약물.
Objective To explore the efficacy of muscovite on iodoacetamide-induced ulcerative colitis in rats and elucidate its possible mechanism.Methods Ulcerative colitis was induced in female Sprague-Dawley (SD) rats by an intracolonic injection of iodoacetamide.A total of 48 rats were divided randomly(by the method of random digits table) into 6 groups:control group,model group,low-dose muscovite group (360 mg/kg),high-dose muscovite group (720 mg/kg),5-aminosalicylie acid (5-ASA) group and muscovite plus 5-ASA group (combined treatment),and each group had 8 rats.The body weight,disease activity index (DAI),macroscopic damage and microscopic score of rats in each group were subsequently evaluated after dosing for 7 days.The protein levels of tumor necrosis factor-α (TNF-α),interleukin-8 (IL-8) and myeloperoxidase (MPO) activity were detected by enzyme-linked immunosorbent assay(ELISA) while the activity of nuclear facor(NF)-κB was determined by immunohistochemistry.One way ANOVA and rank-sum test were used.Results Mter doing,body weight macroscopic damage,microscopic score,TNF-α concentration,MPO and NF-κB activity of rats in each group were all significantly correlated with the dose of muscovite (r =0.573,-0.647,-0.569,-0.681,-0.811,-0.842,all P ＜ 0.05).High-dose muscovite group had no significant difference with 5-ASA group in body weightt,DAI,macroscopic damage,microscopic score,IL-8 concentration,TNF-α concentration,MPO and NF-κB activities((166 ±5) vs (167±5) g,0.33 (0.00,1.17) vs0.17 (0.00,0.83),2.50 (2.00,4.00) vs 3.00 (2.00,3.00),3.00 (2.00,3.00) vs 2.50 (2.00,3.00),(109±17) vs (111 ±15) pg/ml,(166±38) vs (155 ±45) pg/ml,(52±6) vs (49±4) U/g,7.39±0.42 vs 7.41±0.34,all P＞0.05).The MPO and NF-κB activities of combined treatment group were lower than those of 5-ASA group ((40 ±4) vs (49 ±4) U/g,4.67 ±0.72 vs 7.41 ±0.34,all P ＜0.05).However,other indices showed no significant difference with 5-ASA group (all P ＞ 0.05).Conclusions Rectal administration of muscovite ameliorates colonic inflammation of iodoacetamide-induced colitis.Its underlying mechanism is probably due to the regulation of inflammatory response.Muscovite may be a potential therapeutic agent for treatment of ulcerative colitis.
